TP53 and B-cell chronic lymphocytic leukemia: In our study, we found that NDRG2 expression was significantly reduced in CLL patients with p53 aberrations, yet increased by transfecting with related miRNAs-inhibitors promoting CLL cells apoptosis without p53 aberrations.